Dr. Dayan Goodenowe opened the sold-out 2026 Elite Practitioner Event in Carlsbad, California, with a keynote that spanned the full arc of his work. From the published science connecting plasmalogen levels to cognitive health and brain function, to the structural failures in public health policy that prevent dietary compounds with strong evidence from ever reaching the people who need them.
The centrepiece of the presentation was a major announcement: the formal launch of Dr. Goodenowe Dietary Therapeutics, a new company dedicated to obtaining full FDA drug approval for critical dietary supplements, starting with ProdromeNeuro. A purpose-built drug manufacturing facility is in final construction in Moose Jaw, Saskatchewan, clinical trial facilities with advanced MRI are coming online in both Moose Jaw and Temecula, California, and the team is targeting a Phase 2b clinical trial in 2027 with full FDA approval projected by 2029.
Prodrome Sciences will continue operating separately as a dietary supplement company, with ProdromeNeuro, the supplement rebranded as Plasmalogen N3.
The keynote also featured powerful video testimonials from families and individuals across a wide range of health journeys, an update on the Moose Jaw Vitality Project — now serving over 120 community members — including the launch of the new Senior Engage daily drop-in program, and a look ahead at what it means to be an elite practitioner in this growing network.
The message Dr. Goodenowe left the room with: systematic science, real outcomes, no fads — and a future where this approach becomes standard of care.
This content is educational and includes forward-looking statements regarding drug development timelines. Please consult a qualified health professional before making health-related decisions.